 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > United Therapeutics Corporation
 |
United Therapeutics Corporation |
 |
 |
 |
NEWS FROM THE WIRES |
 |
United Therapeutics shrs jump on FDA panel decision Aug 10 2001 11:57 AM PDT
FDA panel backs United Therapeutics' Remodulin Aug 09 2001 10:19 AM PDT
Two lung treatments face key U.S. panel review Aug 08 2001 03:51 PM PDT
Two lung treatments face key U.S. panel review Aug 08 2001 01:02 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
United Therapeutics hopes its products will be in vein. The firm's lead drug candidate, Remodulin, treats both pulmonary hypertension, which affects the blood vessels between the heart and lungs, and peripheral vascular disease, which affects blood vessels in the legs. Other products in the pipeline are being developed to treat chronic obstructive pulmonary disease, cardiovascular disease, hepatitis B and C, and HIV. United Therapeutics has two commercialized products: HeartBar (which contains arginine), a food product that helps treat vascular disease, and CardioPAL, a device for monitoring the internal functions of those susceptible to arrhythmia and angina.
COMPETITION |
 |
Actelion Ltd. (dossier)
Schering AG (SHR)
Texas Biotechnology Corporation (TXBI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 2.00
1-Yr. Sales Growth: 400.0%
Employees: 110
Revenue per employee: $18,181.82
KEY PEOPLE |
 |
Martine A. Rothblatt
CEO
Fred T. Hadeed
CFO
CONTACT INFO |
 |
1110 Spring St.
Silver Spring, MD 20910
US
Phone: 301-608-9292
Fax: 301-608-9291
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |